CROSSJECT (EPA:ALCJ) | Finanzwire

Basculer en Français

10936	Companies
238806	Keywords
167668	Articles
128368	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 05/20/2025 at 07:30, 1 year 3 months ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 1 year 3 months ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
BRIEF

published on 03/27/2025 at 07:35, 1 year 5 months ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 1 year 5 months ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 1 year 5 months ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency
PRESS RELEASE

published on 03/25/2025 at 07:30, 1 year 5 months ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
CROSSJECT enhances collaboration with ETON PHARMACEUTICALS Inc. on ZENEO adrenal insufficiency program, introducing new hydrocortisone formulation for the hospital market

Eton Pharmaceuticals Crossject Hydrocortisone Adrenal Insufficiency ZENEO
BRIEF

published on 03/10/2025 at 14:22, 1 year 5 months ago

Crossject: Update on voting rights and shares as of January 31, 2025

Share Capital Voting Rights Actions Pharmaceutical Crossject
BRIEF

published on 02/12/2025 at 07:35, 1 year 6 months ago

Crossject Reappoints Key Members to Executive Board

Executive Board Crossject ZEPIZURE® Reappointment Needle-free Technology
PRESS RELEASE

published on 02/12/2025 at 07:30, 1 year 6 months ago

Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board
Crossject reappoints Patrick Alexandre and Isabelle Liebschutz to its Executive Board, focusing on final stages of ZEPIZURE registration with the FDA

Executive Board Crossject Patrick Alexandre Isabelle Liebschutz ZEPIZURE Registration
BRIEF

published on 02/06/2025 at 07:35, 1 year 6 months ago

Modification of Convertible Bonds by Crossject

Convertible Bonds Funding Crossject ZEPIZURE Heights Capital

Accesswire

Published on 09/05/2026 at 04:05, 3 hours 34 minutes ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 8 hours 9 minutes ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 8 hours 39 minutes ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 9 hours 9 minutes ago

Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 17 hours 9 minutes ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/04/2026 at 22:10, 9 hours 28 minutes ago

Quantinuum to Participate in the Bernstein 23rd Annual Pan-European Strategic Decisions Conference
Published on 09/04/2026 at 19:20, 12 hours 18 minutes ago

Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 18:55, 12 hours 44 minutes ago

Holding(s) in Company
Published on 09/04/2026 at 18:50, 12 hours 48 minutes ago

A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset
Published on 09/04/2026 at 18:05, 13 hours 33 minutes ago

Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership

Les Echos

Published on 09/04/2026 at 18:57, 12 hours 42 minutes ago

Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 13 hours 54 minutes ago

Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 17:45, 13 hours 54 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 09/04/2026 at 16:00, 15 hours 39 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 15 hours 39 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026

View all LES ECHOS COMFI WIRE